

Therapeutic effects of *Rosa Canina*, *Urtica Dioica* and *Tanacetum Vulgare* Herbal Combination in Treatment of Tinnitus Symptoms; A Double-blind Randomized Clinical Trial

Mohammad Hossein Khosravi, MD,¹ Amirhomayoun Atefi, MD,² Afsaneh Mehri, PharmD,³ Fatemeh Sodeifian, MD,⁴ Jaleh Yousefi, MD,⁵ Ali Bagheri Hagh, MD,⁵ Saeed Sohrabpour, MD,⁶ Fatemeh Kazemi, MD,⁷ Mohammad Ajallouei, MD,⁸ and Masoumeh Saeedi, MD,^{8*}

1. Department of Research, Arka Education and Clinical Research Consultants, Tehran, Iran
2. Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3. Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
4. Student research Committee, School of Medicine, Shahid Beheshti University of medical science, Tehran, Iran
5. Department of Otorhinolaryngology, Faculty of Medicine, Baqiyatallah University of Medical Sciences, Tehran, Iran
6. Otorhinolaryngology Research Center, Tehran University of Medical Sciences, Tehran, Iran
7. Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran
- *8. New Hearing Technologies Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

Correspondence to: Masoumeh Saeedi, New Hearing Technologies Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran

m.saeedi67@gmail.com

+98 912 219 2388

Word count for abstract:

Word count for text:

Background: Tinnitus is defined as the perception of sound in the ear or head in the absence of an external stimulus for which we have no definite treatment. Neurotec® is a medication of herbal origin with IFDA approval. Previous studies showed the neuroprotective effect of Neurotec®. In this study we evaluated the effectiveness of Neurotec in improving tinnitus symptoms.

Methods: This double-blind randomized clinical trial was performed on patients with tinnitus. Patients received Neurotec 100 mg capsules (BID) or placebo for three months. Pure tone audiometry (PTA) was measured at 0.5, 1, 2, 4 and 6 KHz frequencies. Using a Tinnitus Handicap Inventory (THI) questionnaire, tinnitus loudness, daily annoyance, daily life or sleep disturbance, daily perception and mood alteration were evaluated.

Results: Finally, 103 (69 male and 34 female) patients with a mean age of 51.33 ± 13.91 years were analyzed. There was no significant difference between the intervention (n=53) and the control group (n=50) regarding baseline symptoms before and one month after the intervention ($P > 0.05$). While, they were significantly different three months after the intervention ($P < 0.05$). The mean pure tone air and bone conduction were not significantly different between the control and the intervention group before and three months after the intervention at 0.5, 1, 2 and 4 kHz ($P > 0.05$). The mean pure tone air conduction was not significantly different between the two groups before and three months after the intervention at 6 kHz ($P > 0.05$).

Conclusion: A three-month treatment with Neurotec Capsules beside patient education can effectively control symptoms of patients with tinnitus.

Key words: Rosa Canina, Urtica Dioica, Tanacetum Vulgare, Tinnitus and Neurotec

Therapeutic effects of *Rosa Canina*, *Urtica Dioica* and *Tanacetum Vulgare* Herbal Combination in Treatment of Tinnitus Symptoms; A Double-blind Randomized Clinical Trial

Introduction:

Tinnitus or ringing in the ear is defined as the conscious perception of sound in the ear or head in the absence of an external stimulus which is recognized in about 10-15% of people¹. About one to two percent of world population suffer from highly disabling presence of ear noise and developing comorbid conditions such as depression, demoralization and social withdrawal³.

It has been shown that various social factors including low education level, poor income, and some types of occupational activities increasing the noise exposure, lead to development of tinnitus¹. Furthermore, medical conditions such as trauma, hearing loss, or ototoxic treatments are associated with development of tinnitus. Tinnitus is not considered a disease, but rather it is mainly considered as symptom and presentation of underlying medical conditions⁴.

The exact etiology of tinnitus is not well understood. Traditionally, tinnitus has been considered as ontological disorder. However, advancement in neuroimaging and animal models have demonstrated that it could be associated with neuronal interactions. Enhanced neuronal firing rate, increased neuronal synchrony, altered tonotopic organization of brain pathway, as well as alteration in non-auditory brain areas are considered as possible mechanisms involved in development of tinnitus².

So far, there is no available medication that could completely resolve the symptoms of tinnitus and most available treatments help patients to cope with tinnitus and increase their quality of life⁵. In addition to pharmacotherapy, other treatments such as cognitive and behavioral therapy, sound therapy, music therapy, acupuncture, and hearing aids have been suggested for improvement of tinnitus^{4, 6}. Herbal medication such as Ginko Biloba and Gushen Pian (Chinese herbal medication) are considered as an alternative treatment for tinnitus⁶. However, there are not enough and well-designed study to recommend these medications for treatment of tinnitus.

Neurotec® is a medication of herbal origin which contains extracts of dog-rose (*Rosa Canina*), common nettle (*Urtica Dioica*) and tansy (*Tanacetum Vulgare*). Neurotec® is an IFDA approved medication for treatment of peripheral neuropathies in diabetic patients and exerts its action through improving neural message conduction. According to a previous studies, combination of herbal extracts including *Rosa Canina*, *Urtica Dioica* and *Tanacetum Vulgare*, can significantly improve motor function of cerebral ischemic rats and has a protective effect against ischemic brain injury ⁷. In addition, since Neurotec® ingredients have improved spatial learning and memory in rat models of Alzheimer disease, its anti-oxidant and anti-inflammatory effects can be used as a neuroprotective herbal combination ⁸.

Considering all the above mentioned points and according to neuroprotective role of Neurotec ingredients, we hypothesized that it can improve auditory nerve function resulting in better environmental sound perception and consequent reduced tinnitus symptoms. In this study, we used a standardized dose of Neurotec in a double-blinded randomized clinical trial to determine whether it can be effective for management of tinnitus symptoms.

Materials and methods:

Following registration at ethics committee of Baqiyatallah University of Medical Sciences (Ref. No: IR.BMSU.REC.1395.176) and Iranian Registry of Clinical Trials (Ref. No: IRCT2017042817413N23), this double-blind randomized clinical trial was conducted on patients with tinnitus, who attended otolaryngology clinic of Baqiyatallah Hospital between 2015 and 2016. All participants provided written informed consent—this study adhered to the principles of the Declaration of Helsinki. Figure 1 shows a flowchart of the trial.

Patients were assessed for eligibility by an otolaryngologist. Patients with chief complaint of subjective tinnitus for at least 6 months and those above 19 years of age were included in the study. Patients over 75 or below 19 years of age, pregnant women, those with chronic or acute neurological diseases, concomitant psychiatric illnesses, pulsatile tinnitus and underlying conditions such as epilepsy, multiple sclerosis, and history of severe head and neck trauma or ear surgery were excluded from the trial. In addition, patients should not have taken any medication for treatment of tinnitus within at least one month prior to intervention.

Patients were randomly allocated to intervention and control groups using random number table. Patients in intervention group were treated with Neurotec 100 mg capsules (BID) for three months. Patients in control group received placebo capsules, which had exactly the same shape and packaging with Neurotec 100 mg capsules, for the same duration. Patients in both groups received primary tinnitus treatments including reassurance and necessary trainings. Placebo capsules were provided by Rose Pharmed®, the Neurotec manufacturer in Iran.

Patients in both groups underwent pure tone audiometry (PTA) before and three months after intervention. Auditory threshold of patients was measured at 0.5, 1, 2, 4 and 6 KHz frequencies.

Validated Persian version of Tinnitus Handicap Inventory (THI) questionnaire was administered to patients in both groups prior to, one month and three months after intervention⁹.

A zero-to-ten visual analog scale (VAS) was used to evaluate tinnitus loudness, daily annoyance, disturbance in daily life, daily tinnitus perception, sleep disturbance and mood alteration. Data were analyzed using Statistical Package for Social Sciences (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp). Descriptive analysis was performed using mean and standard deviation as well as percentages and frequencies. Kolmogorov-smirnov test was used to check the normal distribution of data. Chi-square test was used to compare the categorical variables and Fisher's exact test if they were not normally distributed. Comparison between groups was performed using t-test, ANOVA, Kruskal-Wallis, Wilcoxon-signed rank and Mann-Whitney U test. A p-value of less than 0.05 was considered as statistically significant.

Results:

Finally, a total of 103 patients (53 cases in intervention and 50 in control group) with a mean age of 51.33 ± 13.91 years underwent analysis. Among the patients, 69 (67%) were male with a mean age of 49.39 ± 15.02 and 34 (33%) were female with a mean age of 55.26 ± 10.47 ($p=0.024$).

There was no statistically significant differences between the mean age of patients in intervention (52.96 ± 14.64) and control (49.60 ± 13.02) groups ($p=0.222$).

The intervention group included 35 (66%) and the control group included 34 (68%) male patients. The gender distribution was not significantly different between the two groups ($p=0.834$). Twenty five (24.3%) patients had right side, 40 (38.8%) had left side and 38 (36.9%) patients had bilateral tinnitus.

Among the patients, 36 patients (35%) had tinnitus symptoms for less than a year; 28 patients (27.2%) had symptoms for one to three years; 16 patients (15.5%) had symptoms for three to eleven years and 23 patients (22.3%) had symptoms for more than eleven years.

Patients' Symptoms:

About all patients' symptoms, such as tinnitus loudness, annoyance severity, daily life alteration, daily tinnitus perception, sleep alteration, mood disturbance and quality of life, there was no significant difference between the intervention group and the control group, before the intervention and one month after the intervention. While there was a significant difference between the intervention group and the control group, three months after the intervention, as shown in **Table 1**.

Table 1: Mean THI and VAS scores before, one month and three months after intervention

Patients' symptoms		Intervention group (N=53)	Control group (N=50)	P value
Tinnitus loudness score	Before intervention	7.19 ± 2.17	6.68 ± 2.63	0.282
	One month after intervention	6.37 ± 2.14	6.29 ± 2.59	0.866
	Three month after intervention	4.92 ± 2.22	5.96 ± 2.85	0.043

Annoyance severity score	P value	0.00	0.034	
	Before intervention	7.25±2.46	7.05±2.57	0.691
	One month after intervention	6.36±2.13	6.36±2.13	0.997
	Three month after intervention	4.79±2.15	6.26±2.46	0.002
Daily life alteration score	P value	0.00	0.001	
	Before intervention	6.08±2.84	5.57±2.99	0.376
	One month after intervention	5.37±2.48	5.48±2.97	0.849
	Three month after intervention	4.14±2.21	5.38±2.87	0.012
Daily tinnitus perception score	P value	0.00	0.880	
	Before intervention	7.36±2.68	6.36±3.02	0.079
	One month after intervention	2.42±6.23	5.96±3.10	0.625
	Three month after intervention	4.5±2.33	5.82±2.87	0.012
Sleep disturbance score	P value	0.00	0.138	
	Before intervention	5.76±3.52	5.67±3.48	0.890
	One month after intervention	4.95±2.98	4.56±2.87	0.498
	Three month after intervention	3.38±2.60	4.84±2.99	0.010
Mood disturbance score	P value	0.00	0.002	
	Before intervention	5.86±3.30	5.26±3.10	0.348
	One month after intervention	5.37±2.75	4.80±2.98	0.315
	Three month after intervention	3.97±2.30	5±2.83	0.045
Quality of life score(THI score)	P value	0.00	0.621	
	Before intervention	58.22±25.13	52.92±28	0.313
	One month after intervention	49.09±22.22	48.36±27.46	0.882
	Three month after intervention	37.52±20.69	49.72±29.23	0.017
	P value	0.00	0.370	

Audiometric Test:

Pure tone audiometry thresholds were analyzed in two frequency groups: low frequency (LF: 0.5, and 1 kHz) and high frequency (HF: 2, 4, and 6 kHz).

The pure tone air conduction average was not significantly different between the control group and the intervention group before the intervention and three months after the intervention at 0.5,1,2 and 4 kHz. The pure tone bone conduction average was not significantly different between the control group and the intervention group before the intervention and three months after the intervention at 0.5,1,2 and 4 kHz. The pure tone air conduction average was not significantly different between the control group and the intervention group before the intervention and three months after the intervention at 6 kHz as shown in **Table 2**.

Table 2: Pure tone audiometry results before and after the 3rd month of intervention.

Frequency			Intervention group(N=53)	Control group(N=50)	P value
0.5 kHz	Pure tone air conduction	Before intervention	24.56±18.61	22.76±14.91	0.589
		Three months after the intervention	24.52±18.31	21.64±13.67	0.369
		P value	0.796	0.317	
	Pure tone bone conduction	Before intervention	15.22±15.28	13.08±8.08	0.372
		Three months after the intervention	14.88±13.79	12.82±8.23	0.362
		P value	0.513	0.617	
1 kHz	Pure tone air conduction	Before intervention	26.11±20.48	27.04±14.40	0.792
		Three months after the intervention	25.47±19.06	22.78±13.81	0.416
		P value	0.131	0.00	
	Pure tone bone conduction	Before intervention	17.26±16.34	16.96±10.18	0.911
		Three months after the intervention	16.73±15.27	15.84±10.21	0.729
		P value	0.088	0.257	
2 kHz	Pure tone air conduction	Before intervention	29.43±19.42	30±14.85	0.869
		Three months after the	27.66±18.70	29.18±16.73	0.665

4 kHz	Pure tone bone conduction	intervention			
		P value	0.00	0.034	
		Before intervention	20.75±14.64	20.08±12.32	0.801
	Pure tone air conduction	Three months after the intervention	19.66±13.62	18.78±12.49	0.734
		P value	0.002	0.144	
		Before intervention	46.18±26.15	46.72±22.07	0.912
	Pure tone air conduction	Three months after the intervention	42.60±24.76	43.58±20.69	0.829
		P value	0.00	0.00	
		Before intervention	35.75±21.98	35.70±18.69	0.989
	6 kHz	Pure tone bone conduction	Three months after the intervention	33.07±20.43	34.12±18.34
P value			0.00	0.034	
Before intervention			53.79±29.42	50.04±24.02	0.482
Pure tone air conduction		Three months after the intervention	50.88±29.75	48.06±23.35	0.592
		P value	0.000	0.009	
		Before intervention			

Discussion:

A variety of herbal extracts have been so far proposed for management of tinnitus; from Ginkgo biloba (Jinko) to garlic and *Yoku-kan-san*¹⁰. To the best of our knowledge this is the very first study which has assessed the therapeutic effect of Neurotec (herbal combination of *Rosa Canina*, *Urtica Dioica* and *Tanacetum Vulgare*) on symptoms of patients with tinnitus.

We found that a three-month treatment with Neurotec beside baseline conservative treatments, significantly decreased scores of tinnitus loudness, annoyance severity, daily life alteration, sleep disturbance, daily tinnitus perception and mood disturbance in intervention group. On the other hand, control group- which was treated only by baseline educational counselling and placebo-showed the same results except for mood disturbance, daily tinnitus perception and daily life alteration scores. This is in line with results of a recently published meta-analysis in which Xiang et al., concluded that educational counseling alone is as effective as other psychological therapies for improving tinnitus and related problems¹¹. In addition, we realized that these improvements were significantly higher for the intervention group. Although patients in intervention group showed a remarkable decrease in THI score (quality of life) after three months of treatment, but those in control group experienced no significant decrease in this score.

For intervention group, pure tone air and bone conduction were significantly improved at 2, 4 and 6 kHz frequencies, after three months of treatment with Neurotec. Pure tone bone conduction did not show any significant improvement in control group at all the frequencies. However, air conduction was significantly improved in all the frequencies except 0.5 kHz.

Ghasemi et al. in an animal study concluded that *Urtica Dioica* extract has positive effects on learning abilities and memory impairments in wistar rats. They explained this as protective characteristic of *Urtica Dioica* against oxidative damage of brain tissues and acetyl choline esterase (AChE) activity¹². In another animal study, Patel et al. reported that *Urtica Dioica* can remarkably reverse diabetes chronic complications such as central and peripheral neuropathies in adult Swiss albino mice¹³. A recently conducted animal study, has reported that *Urtica Dioica* extracts can effectively improve neuro-inflammation and Alzheimer-like phenotypes in rats¹⁴.

Neuroprotective effects of *Rosa Canina* has been evaluated in various settings as in Erfani et al. study which resulted in cognitive and memory improvements in heat stress-exposed rats

¹⁵. Assessing diabetic albino mice, Farajpour et al. showed that hydro-alcoholic extract of Rosa Canina improves memory impairment through modulation of oxidative stress ¹⁶. In 2016, Daneshmand et al. proved the neuroprotective effects of Neurotec ingredients on rat model of sporadic Alzheimer's disease ¹⁷. Setarud (IMOD™) is an immunomodulatory drug consisted from herbal extracts of Rosa Canina, Tancetum Vulgare and Urtica Dioica. In an animal study, vafae et al. showed that setarud has a neuroprotective effect against brain ischemia in rat models ¹⁸. As mentioned before, Neurotec is a safe and IFDA-approved medication for neuropathic pains, especially in diabetic patients.

Pathologies from the ear canal to the auditory cortex, may be responsible for tinnitus perception ¹⁹. Auditory neural plasticity is one of the considered mechanisms, which knows cochlear deafferentation as trigger, and subsequent changes in central nervous system as the cause for maintenance of tinnitus perception ²⁰. We hypothesized that these neuroprotective features of Neurotec, improve cochlear nerve function and neural conduction; thus, this improvement results in better perception of environmental sounds and consequently decreases tinnitus perception. This is also the rational behind sound therapy by which, low- to moderate- level sound stimulation reverse the role of auditory deprivation in inducing tinnitus and hyperacusis ²¹.

Apart from herbal and chemical medications, a wide range of medical and non-medical treatment modalities have been evaluated for management of tinnitus; from non-invasive interventions such as yoga and meditation, sound therapy and smartphone applications to minimally- and invasive interventions like acupuncture and surgical neuromodulation ²¹⁻²⁵. Despite all these efforts, no curative treatment has been so far developed for Tinnitus. It seems that patients may take benefits from an intellectual combination of these treatments²⁶. On the other hand, herbal medications and extracts are an appropriate alternative therapy as they are both more tolerated by patients and have less side effects²⁶.


The present study has some limitations. We had loss to follow ups in both intervention and placebo groups which may be attributable to nonsensible effects of treatment for patients, especially in initial weeks and month.

In conclusion, we found that a three-month treatment with Neurotec capsules accompanied by educational counselling is of benefit for managing symptoms in patients with chronic tinnitus. Further studies with a larger sample size and also longer duration of follow up are recommended.

Reference

1. Haider HF, Hoare DJ, Costa RFP, Potgieter I, Kikidis D, Lapira A, et al. Pathophysiology, Diagnosis and Treatment of Somatosensory Tinnitus: A Scoping Review. *Front Neurosci* 2017;11(207).
2. Langguth B, Kreuzer PM, Kleinjung T, De Ridder D. Tinnitus: causes and clinical management. *Lancet Neurol* 2013;12(9):920-30.
3. Rief W, Weise C, Kley N, Martin A. Psychophysiologic treatment of chronic tinnitus: a randomized clinical trial. *Psychosom Med* 2005;67(5):833-38.
4. Han BI, Lee HW, Kim TY, Lim JS, Shin KS. Tinnitus: characteristics, causes, mechanisms, and treatments. *J Clin Neurol* 2009;5(1):11-9.
5. Atik A. Pathophysiology and treatment of tinnitus: an elusive disease. *Indian J Otolaryngol Head Neck Surg* 2014;66(Suppl 1):1-5.
6. Luetzenberg FS, Babu S, Seidman MD. Alternative Treatments of Tinnitus: *Alternative Medicine. Otolaryngol Clin North Am* 2020;53(4):637-50.
7. Vafaei F, Zangiabadi N, Pour FM, Dehghanian F, Asadi-Shekaari M, Afshar HK. Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats. *Neural Regen Res* 2012;7(27):2085-91.
8. Daneshmand P, Saliminejad K, Dehghan Shasaltaneh M, Kamali K, Riazi GH, Nazari R, et al. Neuroprotective Effects of Herbal Extract (*Rosa canina*, *Tanacetum vulgare* and *Urtica dioica*) on Rat Model of Sporadic Alzheimer's Disease. *Avicenna J Med Biotechnol* 2016;8(3):120-5.
9. Mahmoudian S, Shahmiri E, Rouzbahani M, Jafari Z, Keyhani MR, Rahimi F, et al. Persian language version of the. *The International Tinnitus Journal* 2011;16(2):93-103.
10. Khosravi MH, Saeedi M, Yousefi J, Bagherihagh A, Ahmadzadeh E. Herbal Medicine in the Management of Tinnitus. *Management of Tinnitus-The Enriching Views of Treatment Options* 2018.
11. Xiang T, Zhong J, Lu T, Pu J-m, Liu L, Xiao Y, et al. Effect of educational counseling alone on people with tinnitus: Meta-analysis of randomized controlled trials. *Patient education and counseling* 2020;103(1):44-54.
12. Ghasemi S, Moradzadeh M, Hosseini M, Beheshti F, Sadeghnia HR. Beneficial effects of *Urtica dioica* on scopolamine-induced memory impairment in rats: protection against acetylcholinesterase activity and neuronal oxidative damage. *Drug and chemical toxicology* 2019;42(2):167-75.
13. Patel SS, Udayabanu M. Effect of *Urtica dioica* on memory dysfunction and hypoalgesia in an experimental model of diabetic neuropathy. *Neuroscience Letters* 2013;552:114-19.
14. AH AA, Mosaad R, Hassan M, Ali E, Mahmoud G, Ahmed H, et al. *Urtica dioica* extracts abolish scopolamine-induced neuropathies in rats. *Environmental Science and Pollution Research International* 2021.

15. Erfani M, Ghazi Tabatabaei Z, Sadigh-Eteghad S, Farokhi-Sisakht F, Farajdokht F, Mahmoudi J, et al. Rosa canina L. methanolic extract prevents heat stress-induced memory dysfunction in rats. *Experimental physiology* 2019;104(10):1544-54.
16. Farajpour R, Sadigh-Eteghad S, Ahmadian N, Farzipour M, Mahmoudi J, Majdi A. Chronic administration of Rosa canina hydro-alcoholic extract attenuates depressive-like behavior and recognition memory impairment in diabetic mice: a possible role of oxidative stress. *Medical principles and practice* 2017;26(3):245-50.
17. Daneshmand P, Saliminejad K, Shasaltaneh MD, Kamali K, Riazi GH, Nazari R, et al. Neuroprotective effects of herbal extract (Rosa canina, Tanacetum vulgare and Urtica dioica) on rat model of sporadic Alzheimer's disease. *Avicenna journal of medical biotechnology* 2016;8(3):120.
18. Vafae F, Zangiabadi N, Pour FM, Dehghanian F, Asadi-Shekaari M, Afshar HK. Neuroprotective effects of the immunomodulatory drug Setarud on cerebral ischemia in male rats. *Neural regeneration research* 2012;7(27):2085.
19. Wang K, Tang D, Ma J, Sun S. Auditory Neural Plasticity in Tinnitus Mechanisms and Management. *Neural Plasticity* 2020;2020.
20. Noreña AJ. Revisiting the cochlear and central mechanisms of tinnitus and therapeutic approaches. *Audiology and Neurotology* 2015;20(Suppl. 1):53-59.
21. Pienkowski M. Rationale and efficacy of sound therapies for tinnitus and hyperacusis. *Neuroscience* 2019;407:120-34.
22. Gunjawate D, Ravi R. Effect of yoga and meditation on tinnitus: a systematic review. *The Journal of Laryngology & Otology* 2021:1-4.
23. Mehdi M, Dode A, Pryss R, Schlee W, Reichert M, Hauck FJ. Contemporary Review of Smartphone Apps for Tinnitus Management and Treatment. *Brain Sciences* 2020;10(11):867.
24. Huang K, Liang S, Chen L, Grellet A. Acupuncture for tinnitus: a systematic review and meta-analysis of randomized controlled trials. *Acupunct Med* 2020:964528420938380.
25. Deklerck AN, Marechal C, Pérez Fernández AM, Keppler H, Van Roost D, Dhooge IJ. Invasive neuromodulation as a treatment for tinnitus: a systematic review. *Neuromodulation: Technology at the Neural Interface* 2020;23(4):451-62.
26. Luetzenberg FS, Babu S, Seidman MD. Alternative Treatments of Tinnitus: Alternative Medicine. *Otolaryngologic Clinics of North America* 2020;53(4):637-50.






Figure 1. Study flowchart

Funding

This research was supported by the Baqiyatallah University of Medical Sciences (Ref. No: IR.BMSU.REC.1395.176).

Ethical statement

This study was approved by the Baqiyatallah University of Medical Sciences (Ref. No: IR.BMSU.REC.1395.176). All participants provided written informed consent—this study adhered to the principles of the Declaration of Helsinki .

Data availability

The data for this article will be available upon request.